- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07588048
Morton Toe and Neuromuscular Performance
Morton Toe is Associated With Faster Contractile Properties and Superior Reactive Strength in Female Football Players
Studieoversikt
Status
Detaljert beskrivelse
Morton toe is a congenital foot morphology characterized by a longer second metatarsal relative to the first. Although traditionally regarded as a clinical or orthopedic variation associated with metatarsal stress fractures and balance difficulties, limited evidence from sprinter populations suggests that a longer second toe may be associated with superior athletic performance. However, no previous study has examined whether Morton toe morphology is related to neuromuscular contractile properties assessed via tensiomyography or kinetic performance derived from force plate testing in a controlled group comparison design.
Participants were screened from 97 female football players. Exclusion criteria included BMI outside the 18.5-29.9 range, bilateral arch index outside the 14-29% range, inconsistent bilateral foot morphology, lower-extremity injury within the past 12 months, neurological or orthopedic conditions, performance-affecting pharmacological use, and menstruation on the measurement day. Morton toe classification was based on the palpation method described by Davidson et al. (2007) with a minimal detectable change threshold of ±0.30 mm.
All measurements were conducted during the off-season to minimize training load interference. Testing followed a standardized sequence: foot morphology assessment, tensiomyography of the dominant vastus lateralis at rest, a 15-minute warm-up, and a 40-cm drop jump test. The assessor was blinded to group classification, and statistical analysis was performed by an independent researcher on a coded dataset. Primary outcome variables (Tc and RSI) were determined a priori. Secondary outcomes were corrected for multiple comparisons using the Holm-Bonferroni method. Regression analyses were performed to assess the independence of group effects from age, body mass index, and mean bilateral arch index.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Centre
-
Giresun, Centre, Tyrkia (Türkiye), 28100
- Giresun University - Sports Science Faculty
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Active female football players with a valid sports license for the current season
- Regular participation in training and competitive matches
- Bilateral Morton toe morphology (Δ ≤ -0.30 mm on both feet) or bilateral normal foot morphology (Δ > +0.30 mm on both feet)
- Body mass index between 18.5 and 29.9 kg/m²
- Bilateral arch index between 14% and 29%
- Voluntary participation with written informed consent
Exclusion Criteria:
- Serious lower-extremity musculoskeletal injury within the past 12 months
- Neurological or orthopedic disease affecting measurement procedures
- Current use of pharmacological products affecting performance
- Acute pain, injury, or illness on the measurement day
- Menstruation on the measurement day (self-reported)
- Inconsistent bilateral foot morphology classification between feet
- Bilateral arch index below 14% (high arch) or above 29% (low arch)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Morton Foot Group
Female football players with bilateral Morton toe morphology, defined as a second metatarsal protrusion distance exceeding the first by more than 0.30 mm bilaterally (Δ ≤ -0.30 mm).
n = 24.
|
|
Normal Foot Group
Female football players with bilateral normal foot morphology, defined as a first metatarsal protrusion distance exceeding the second by more than 0.30 mm bilaterally (Δ > +0.30 mm).
n = 23.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Contraction Time (Tc)
Tidsramme: Single measurement session
|
Tensiomyographic contraction time of the dominant vastus lateralis muscle, defined as the time between 10% and 90% of maximal radial displacement (ms).
|
Single measurement session
|
|
Reactive Strength Index (RSI)
Tidsramme: Single measurement session
|
Jump height divided by ground contact time during a 40-cm drop jump test (m/s).
The trial with the highest RSI value out of three attempts was selected for analysis.
|
Single measurement session
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximal Displacement (Dm)
Tidsramme: Single measurement session
|
Peak radial displacement of the vastus lateralis muscle belly during tensiomyographic measurement (mm).
|
Single measurement session
|
|
Relaxation Time (Tr)
Tidsramme: Single measurement session
|
Time from 90% to 50% of maximal displacement during the relaxation phase of tensiomyographic measurement (ms).
|
Single measurement session
|
|
Delay Time (Td)
Tidsramme: Single measurement session
|
Time from electrical stimulus onset to 10% of maximal displacement during tensiomyographic measurement (ms).
|
Single measurement session
|
|
Sustain Time (Ts)
Tidsramme: Single measurement session
|
Duration the muscle response remains above 50% of maximal displacement during tensiomyographic measurement (ms).
|
Single measurement session
|
|
Jump Height (JH)
Tidsramme: Single measurement session
|
Vertical jump height calculated from flight time during a 40-cm drop jump test (cm).
|
Single measurement session
|
|
Peak Power Normalized to Body Mass (PPI)
Tidsramme: Single measurement session
|
Peak power output normalized to body mass during a 40-cm drop jump test (W/kg).
|
Single measurement session
|
|
Landing Net Peak Force Normalized to Body Mass (LPF)
Tidsramme: Single measurement session
|
Peak vertical ground reaction force at landing normalized to body mass during a 40-cm drop jump test (N/kg).
|
Single measurement session
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- GRU-SBF-NS-06
- 10/492 (Annen identifikator: Giresun University Social Sciences, Natural Sciences and Engineering Research Ethics Committee)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .